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Abstract
In view of the growing prevalence of Alzheimer’s disease (AD) worldwide, there is an urgent need for the development
of better diagnostic tools and more effective therapeutic interventions. At the earliest stages of AD, no significant
cognitive or functional impairment is detected by conventional clinical methods. However, new technologies based on
structural and functional neuroimaging, and on the biochemical analysis of cerebrospinal fluid (CSF) may reveal
correlates of intracerebral pathology in individuals with mild, predementia symptoms. These putative correlates are
commonly referred to as AD-related biomarkers. The relevance of the early diagnosis of AD relies on the hypothesis
that pharmacological interventions with disease-modifying compounds are likely to produce clinically relevant benefits
if started early enough in the continuum towards dementia. Here we review the clinical characteristics of the prodromal
and transitional states from normal cognitive ageing to dementia in AD. We further address recent developments in
biomarker research to support the early diagnosis and prediction of dementia, and point out the challenges and
perspectives for the translation of research data into clinical practice.
Introduction
Alzheimer’s disease (AD) is the most common dement-
ing disorder in older people. As a consequence of popu-
lation aging worldwide, a fourfold increase in the
prevalence of AD is expected to occur over the next
decades. Recent estimates foresee that more than 80 mil-
lion individuals will be affected by the disease by 2040,
which is a natural consequence of the age-dependent
increase in the number of incident cases of AD [1-3].
An important contemporaneous challenge in the man-
agement of AD is to establish its early diagnosis, or, ide-
ally, to identify the cases of AD prior to the actual onset
of dementia. This requires the development of new diag-
nostic tools to predict the dementia outcome among
older people with very mild symptoms of cognitive dys-
function, or even in asymptomatic individuals. Although
a few promising methods have been experimentally vali-
dated, the translation of the current knowledge into
clinical practice still requires methodological pruning
and guidance by operational criteria.
The National Institute on Aging and the Alzheimer’s
Association have recently convened working groups to
re-edit the diagnostic criteria for AD dementia, taking
into account the vast expansion of the knowledge of the
neurobiology of the disease, most of which was
obviously unavailable by the time the original National
Institute of Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria were launched
26 years ago [4,5]. Another important accomplishment
of these workgroups was to revise the clinical and biolo-
gical correlates of AD in the symptomatic predementia
phase, yielding the proposition of the diagnostic criteria
for ‘mild cognitive impairment (MCI) due to AD’ [6].
The authors incorporated the use of biomarkers to
define three levels of certainty of the clinical diagnosis,
given the characterization of mild cognitive deficits in
non-demented older people: (i) ‘MCI of a neurodegen-
erative etiology’, in the presence of the typical clinical
presentation of individuals who are at an increased risk
of progression to AD dementia, but have negative or
ambiguous biomarker evidence of the underlying AD
pathology; (ii) ‘MCI of the Alzheimer type’, when the
subject meets the MCI criteria above and, in addition,
has one or more topographic biomarkers associated
with the downstream effects of the AD pathology (for
example, MRI evidence of medial temporal lobe atrophy,
or fluorodeoxyglucose positron emission tomography
(FDG-PET) evidence of decreased temporomedial
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metabolism); and (iii) ‘prodromal Alzheimer’s dementia’,
when the subject meets the MCI criteria above and, in
addition, has a positive biomarker for the molecular
neuropathology of AD (such as molecular imaging of
intracerebral amyloid with PET, or the typical pattern of
the AD-related cerebrospinal fluid (CSF) biomarkers, as
will be discussed below. The latter proposition does not
require, but is reinforced by the topographic (down-
stream) evidence of the AD pathological process, as pro-
vided by structural or functional neuroimaging [6].
In this review article, we address the clinical charac-
teristics of the prodromal stages of AD and the transi-
tional states from normal cognitive ageing and
dementia. We further present recent developments in
biomarker research, and the perspectives of using these
techniques to reinforce the clinical diagnosis of AD at
predementia stages.
Alzheimer’s disease: translating neurobiological
knowledge into clinical practice
AD is a chronic neurodegenerative disease with well
defined pathological markers, mostly affecting medial
temporal lobe and associative neocortical structures.
Neuritic plaques and neurofibrillary tangles, the patholo-
gical hallmarks of AD, are primarily related to the over-
production and aggregation of the amyloid b peptide
(Ab) within the brain, and to the hyperphosphorylation
of Tau protein in affected neurons. These abnormalities
lead to the activation of neurotoxic cascades and to
cytoskeletal changes that eventually cause neuronal dys-
function and death. Neurofibrillary tangles appear first
in allocortical structures, whereas amyloid plaques may
first be found in the neocortex [7]. In addition to amy-
loid accumulation and neurofibrillary pathology, synap-
tic dysfunction leading to neuronal dystrophy are
phenomena proxy to the structural changes of the brain,
which ultimately triggers the clinical syndrome that
characterizes incipient AD [8]. The cognitive manifesta-
tions associated with this process are compatible with
subtle damage to hippocampal and related limbic and
prefrontal structures, and may last for many years until
the functional burden becomes severe enough to sur-
mount the dementia threshold [9] (Figure 1).
There is evidence of a long preclinical phase in AD, in
which the aforementioned abnormalities gradually accu-
mulate in affected brain areas prior to the presentation
of significant cognitive decline and dementia. Recent
models based on neuropathological, biochemical and
neuroimaging methods have proposed that intracerebral
amyloidosis precedes the onset of cognitive symptoms
by several years, if not decades. Autopsy studies have
shown that intracerebral amyloidosis may be observed
in some subjects as early as in the third or fourth dec-
ades of life, with increasing magnitude in late middle
age, and highest estimates in old age [10-12]. The exact
proportion of amyloid-positive normal adults who will
ultimately develop AD is still uncertain, and critically
dependent on the age and genetics of the cohort; yet,
cortical amyloid load in cognitively normal older adults
seems to be associated with a higher rate of progression
to symptomatic AD in the long term [13].
It is a difficult task to clinically differentiate incipient
AD from normal cognitive ageing and from the subtle
cognitive changes that arise in other forms of dementia
in the prodromal phases. In the early stages, patients
with AD may present with mild but persistent (and
often progressive) cognitive deficits, albeit not severe
enough to warrant the diagnosis of dementia. In the
recent literature, individuals in this predementia stage of
AD have been most commonly categorized according to
the definition of MCI [14]. However, it is widely
accepted today that the cross-sectional diagnosis of MCI
selects a clinically and biologically heterogeneous group
of patients, which limits its prognostic value [15]. Given
the insidiously progressive nature of most neurodegen-
erative illnesses, among which AD represents the most
prevalent condition, it is reasonable to assume that most
patients who are prone to become demented will pre-
sent at early stages with symptoms compatible with the
definition of MCI. Nevertheless, the reciprocal assump-
tion may not be true, given the fact that many persons
who fulfill diagnostic criteria for MCI at one particular
assessment will not evolve to dementia at all.
Despite this, the long predementia phase in AD con-
stitutes a unique time frame to search for clinical and
neurobiological tools to reinforce the cross-sectional
diagnosis and to predict the dementia outcome. The
neuropathological features of subjects with amnestic
MCI are intermediate between those found in cogni-
tively normal and demented individuals (Figure 2). In a
clinicopathological study, most patients with amnestic
MCI did not meet the neuropathologic criteria for AD,
but their pathological findings suggested a transitional
state of evolving AD, given the involvement of medial
temporal lobe structures likely accounting for the mem-
ory impairment [16].
Subtle changes related to the pathological process may
be quantified in asymptomatic or mildly symptomatic
patients by the assessment of humoral fluids, mostly
cerebrospinal fluid (CSF), or by using advanced neuroi-
maging methods. Therefore, the rationale for the search
for biological markers in AD is to increase diagnostic
accuracy at early stages of the disease process. The cor-
rect use of this information may help identify subjects at
risk of developing dementia upon follow-up. However,
the clinical benefits will critically depend on the avail-
ability of more efficacious therapies to halt cognitive
decline and, ideally, to prevent dementia. These include
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the development of more specific pharmacological inter-
ventions targeting the pathological cascades of AD.
Predementia in Alzheimer’s disease
The cognitive syndrome of early stage AD is primarily
represented by encoding and retrieval deficits, resulting
in episodic memory impairment and diminished capacity
to learn new information [17-19]. Through clinical
assessment, such deficits may be revealed by memory
tests such as story/picture recall and word list learning.
However, the specificity of these findings may be ques-
tionable, since similar deficits can be found in other pre-
valent conditions in older people, namely depression and
cerebrovascular disease. Studies suggest that AD-prone
patients fail to benefit from associative learning strategies
and from mnemonic cues (for example, cued delayed
recall paradigms). In the recent literature, short-term and
long-term memory binding deficits have been suggested
to be strong predictors of AD in older adults [19]. These
subfunctions of the memory process refer to the ability
to hold multiple sources of information in memory, and
to bind together different aspects of one given stimulus
in order to form integrated memories. These abilities are
required for associative learning, and binding deficits
may be early signs of hippocampal dysfunction. In fact,
AD patients have difficulties in learning associations
between two or more characteristics of the same object
(for example, shape and color), distinct verbal contents of
one given idea, the association between faces and names,
and also to integrate spatial locations to other mnemonic
contents. The clinical progression towards dementia
includes the additional impairment of at least one more
cognitive domain, which is normally represented by
executive dysfunction [20]. Recent data indicate a posi-
tive strong correlation between the magnitude of execu-
tive and functional impairment [21].
Figure 1 Hypothetical model of the pathological processes in Alzheimer’s disease (AD), focusing on the amyloid b peptide (Ab)
cascade. (Other relevant mechanisms have been omitted or presented in a secondary perspective for didactic purposes.) Dotted arrows indicate
possible or secondary mechanisms affecting core pathological processes within the amyloid cascade. Background shades of gray separated by
dotted lines are a schematic representation to integrate the progression of pathological events along with the development of the cognitive
syndrome of AD (these thresholds are arbitrary and not experimentally validated, and represent the authors’ point of view of the disease
process). Three clinical phases of the disease are defined: presymptomatic (or preclinical) AD may last for several years or decades until the
overproduction and accumulation of Ab in the brain reaches a critical level that triggers the amyloid cascade; in the predementia phase,
compatible with the definition of mild cognitive impairment secondary to AD, early stage pathology is present in varying degrees, from mild
neuronal dystrophy to early stage Braak pathology, according to individual resilience and brain reserve. Finally, in the clinically defined dementia
phase, there is a progressive accumulation of the classical pathological hallmarks of AD (that is, neuritic plaques and neurofibrillary tangles),
bearing relationship with the progression of cognitive deficits and the magnitude of functional impairment. APP = amyloid precursor protein;
PS1/2 = presenilin 1/2; TAU = microtubule-associated protein Tau.
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The characterization of the cognitive syndrome that
best predicts the AD outcome in non-demented patients
has been the focus of extensive research in the past dec-
ades. However, the clinical picture of predementia AD
overlaps with the cognitive changes that occur in nor-
mal ageing and other pathological processes. Frequency
estimates of cognitive impairment in the older popula-
tion depend critically on the definition that is adopted
to yield the classification of subjects as normal or
impaired. However, these different definitions not always
agree with respect to the procedures that need to be
adopted to rule in and out subtle cognitive deficits.
In addition, the output obtained from the classification
of individuals according to one given definition of cogni-
tive impairment is highly dependent on the setting.
Community samples are more heterogeneous regarding
to the etiology of cognitive deficits, given the higher
representation of symptoms attributed to medical and
psychiatric causes. In contrast, the proportion of sub-
jects with underlying AD pathology tends to higher in
tertiary services and specialized memory clinics, where
most attendees are actively seeking diagnosis and treat-
ment for their symptoms. Therefore, the diagnosis of
cognitive impairment in community samples may favor
sensitivity in detriment of specificity; conversely, the
positive predictive value of the diagnosis tends to be
higher in patients attending memory clinics. A good
illustration of this problem was published by Stephan et
al. [22], who showed that the prevalence of cognitive
impairment in community dwelling older adults using
different definitions was as variable as 0.1% to 42%. The
authors concluded that the classification of individuals
as cognitively impaired or normal depends critically on
the way criteria are defined and operationalized. Each
classification captures a unique group of individuals,
with little concordance and varying prognostic value.
Thus, there is an urgent need for an agreed-upon stan-
dard case definition to use as a criterion standard.
Mild cognitive impairment
Among the various definitions that have been proposed
to ascertain the clinical signs and symptoms attributed
to the earliest stages of dementia, the Mayo Clinic
description of MCI, launched by the seminal works of
Petersen and collaborators [14], is perhaps the most
widely used term in the recent literature. Originally, this
definition emphasized the presence of memory com-
plaints, with objective demonstration of lower than
expected performance on memory tests; there should be
a global preservation of intellectual function and no
Figure 2 Relationship between the progression of cognitive and functional symptoms and the neuropathological events in the
transition from asymptomatic Alzheimer’s disease (AD) to mild cognitive impairment due to AD and clinically manifest dementia of
the AD type.
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evidence of functional impairment. A higher risk to pro-
gress to AD upon follow-up (approximately 10% per
year) was attributed to subjects diagnosed as with MCI.
A few years later, the definition of MCI was broadened
to encompass deficits in other cognitive domains, such
as language, attention and executive functions, and also
to differentiate cases with association of deficits on one,
two or more cognitive domains (that is, amnestic and
non-amnestic, single-domain or multiple-domain MCI)
[23,24]. Specific patterns of cognitive impairment would
indicate a higher risk of distinct dementia outcomes.
Several other clinical and epidemiological investiga-
tions have also demonstrated that patients with MCI
progress more often to AD or to other dementias than
older adults without objective evidence of cognitive
impairment. However, a substantial variation in the
annual progression rates from MCI to AD is observed
across studies, ranging from low estimates of 3% to very
high estimates of 40% to 50% in samples defined accord-
ing to the Mayo Clinic diagnostic criteria for MCI
[25,26]. Several reasons have been pointed out to
explain these discrepancies in conversion rates, particu-
larly the magnitude of cognitive deficits at baseline
(even though within definition limits) and the imprecise
definition of functional impairment to differentiate MCI
from dementia. Considering the arbitrary psychometric
threshold for caseness based on the performance on
cognitive tests (usually defined as 1.0 to 1.5 standard
deviations below age-corrected and education-corrected
population norms), the definition of MCI still accepts a
relatively wide range of cognitive deficits, both in quan-
titative and qualitative terms. In addition, no guidelines
have so far been provided to operationalize the cognitive
assessment of patients (that is, which cognitive domains
must be assessed in addition to memory), and which
tests are more adequate for distinct populations, taking
into account age-dependent, educational and cultural
sources of bias [27]. Therefore, different assessment pro-
tocols to determine the degree of cognitive impairment
may result in varying estimates of the cognitive deficits:
more stringent tests are more sensitive to detect mild
impairment of memory and other cognitive functions,
whereas comprehensive batteries (for example, formal
neuropsychological assessment) will more likely identify
impairments in other cognitive functions beyond mem-
ory, favoring the identification of non-memory deficits
and the diagnosis of multiple-domain MCI. As opposed
to that, brief (function-oriented) cognitive batteries and
screening tests may focus on the assessment of memory
and overlook other cognitive domains. Thus, the lack of
methodological uniformity to ascertain the degree and
type of cognitive impairment across studies explains in
part the discrepancies in prevalence and conversion
rates [15].
The prognostic value of the MCI subtypes is an
important issue on debate. The early definition of
amnestic MCI supported the notion that the patients
would present at the early stages of AD with signs of
episodic memory impairment and progress linearly to a
full-blown dementia syndrome. A similar assumption
was attributed to other MCI subtypes and respective
(theoretical) outcomes [28] (Figure 3). Nevertheless, epi-
demiological and clinical studies have questioned the
association between MCI subtypes and specific dementia
outcomes [29,30]. Individuals initially diagnosed as with
MCI may show a long-term stability of cognitive deficits
or even return to normal standards over time [31-33].
In fact, a substantial proportion of such patients may be
reclassified as cognitively normal in a future evaluation.
These cases are usually reported as ‘unstable MCI’. It is
still to be defined whether the first diagnosis was a
false-positive artifact of cognitive testing, or if these
individuals do recover normal cognitive function after
having transient, subtle impairment. As it is, diagnostic
instability is found in 5% to 20% of longitudinal samples
of MCI [33]. These estimates tend to be inversely corre-
lated with the level of certainty of raters on the clinical
relevance of deficits at baseline.
Early studies assumed a linear trend between healthy
cognition to MCI and dementia in older adults. These
notions were based on analytical approaches that used
time to event or last observation carried forward.
Despite useful to determine conversion rates, these stu-
dies were not informative of the pattern of transitions
between different clinical states. A different analytical
strategy based on the Markov Chain model addressed
the transitions between intact cognition, dementia and
death in a subset of the Nun Study [34]. This model
defines absorbing and non-absorbing states, which
respectively represent the irreversible diagnoses of
dementia (AD) or death, and the possibly reversible (or
transitional) states of MCI. In this perspective, a plausi-
ble pattern of transitions between normal cognitive
function, MCI and the diagnosis of AD could be: cogni-
tively healthy subjects first develop single-domain
amnestic deficits (incident MCI); upon follow-up, these
subjects may retain this diagnosis (in spite of the possi-
ble exacerbation of memory impairment), or eventually
develop deficits in other cognitive domains in addition
to memory (usually attention and/or executive dysfunc-
tion). In this case, the diagnosis of single-domain
amnestic MCI is updated to multiple-domain amnestic
MCI. These patients may partially recover and return to
the previous classification, but most commonly they
retain the multiple-domain MCI status until the pro-
gression of memory and non-memory (mostly dysexecu-
tive) deficits triggers functional impairment. At this
point the clinical picture becomes compatible with mild
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dementia, and the diagnosis of dementia of the AD type
is warranted. Reversal of deficits from this point
becomes highly unlikely, which characterizes the absorb-
ing state of dementia (AD) [20].
Therefore, the characterization of functional impair-
ment is critical to establish the threshold between MCI
and incipient dementia. Clinical and epidemiological
studies have shown that patients with MCI may present
subtle impairment in complex, instrumental activities of
daily living (IAVDs), albeit not sufficient to impair inde-
pendent living [35-38]. This is acceptable for the diagno-
sis of MCI according to the Mayo Clinic criteria [14].
Studies have suggested that the aggravation of functional
deficits may occur independently of the worsening of
memory impairment [39]. However, the magnitude of
instrumental deficits to characterize conversion to
dementia, given the prior diagnosis of MCI, has not
been objectively defined, and this diagnosis depends pri-
marily on clinical judgment.
This is important because the characterization of mild
deficits in IAVDs in patients with MCI may hold a
prognostic significance (that is, a higher risk to progress
to AD/dementia). The objective evaluation of functional-
ity has so far been neglected in the diagnostic investiga-
tion. It normally relies on the subjective report of
patients and caregivers, or on the administration of
functional scales to caregivers. There are several sources
of bias in this form of assessment, namely the cognitive
state of caregivers, the pattern of relationship between
the patient and caregiver, their mood state and person-
ality characteristics [40,41]. Thus, there is an urgent
need for a better definition of functional impairment
and for the operationalization of this assessment. In a
recent study conducted in our group, the objective
assessment of functional state provided evidence that
patients with MCI may have mild but significant impair-
ment in higher-order activities of daily living, such as
shopping skills and managing finances, as compared to
healthy older controls [42]. Functional deficits in
patients with MCI and AD display a high and significant
correlation with the performance on executive functions
[21], and seem to be independent of age and formal
schooling [43]. The magnitude of functional impairment
in patients with MCI is similar among converters and
non-converters, supporting the notion that mild func-
tional impairment in also a feature of non-demented
patients; however, a significant correlation between
functional impairment and concentrations of phosphory-
lated Tau was found in the CSF of MCI patients who
progressed to dementia [42], indicating that objective
measures of IAVDs deficits is also correlated with well
defined predictors of conversion.
As reviewed above, the concept of MCI may be sensi-
tive to identify subjects that may develop AD/dementia,
since most, if not all, individuals with predementia AD
will present, at some point of the progression curve,
with a long period of mild cognitive deficits prior to the
onset of dementia. Nevertheless, as currently conceived,
Figure 3 Hypothetical outcomes according to distinct mild cognitive impairment (MCI) subtypes [14,23].
Forlenza et al. BMC Medicine 2010, 8:89
http://www.biomedcentral.com/1741-7015/8/89
Page 6 of 14
the clinically oriented diagnostic criteria for MCI yield a
heterogeneous group of patients with distinct short-
term and long-term outcomes. In other words, the spe-
cificity and the predictive value of the MCI diagnosis
are low, and the cross-sectional identification of cases of
prodromal AD may not reach adequate diagnostic accu-
racy if based solely on clinical tools [15]. Rather, it bene-
fits substantially from the combination of clinical and
biological information. In the next sections we will
revise the recent developments on biochemical and neu-
roimaging biomarkers for the early diagnosis of AD. Of
course, if such tests are unavailable, which may be the
case in most healthcare settings, particularly in less
favored countries, the expert interpretation of test
results, the criterious observation of longitudinal mea-
sures, including the careful judgment of all available
variables, is certainly the best alternative to drive clinical
decisions.
The search for biological biomarkers of
Alzheimer’s disease
The development of biomarker research in AD is a good
example of the successful effort to translate the knowl-
edge of key pathophysiological mechanisms of the disease
into clinical applications. A biomarker is a characteristic
that can be measured and evaluated as an indicator of
the pathogenetic processes, or to ascertain the effect of
pharmacological interventions on predefined biological
cascades [44]. The ideal diagnostic marker for AD should
meet at least three basic requirements: (i) reflect core
neurobiological changes that characterize the disease
process; (ii) be validated by post mortem studies, assum-
ing that the neuropathological findings are gold stan-
dards of abnormalities affecting the same cascade; and
(iii) be measurable as early as possible in the disease con-
tinuum, ideally at presymptomatic stages. Additional
requirements include being non-invasive and simple to
perform, precise and reliable, and adequate for large-
scale screenings. Among many candidate markers, none
has so far achieved universal acceptance, nor fully met
the abovementioned criteria. Nonetheless, there has been
significant progress toward this goal in the areas of CSF
and neuroimaging biomarker identification, with atten-
tion focusing on the prediction of AD in the prodromal
stages of disease and in high-risk groups.
CSF biomarkers
The CSF may be considered an ideal source for viable bio-
markers in AD. It is in intimate contact with the cerebral
tissue, and pathological changes in the brain are often
reflected in the CSF [45]. Among several potential diag-
nostic biomarkers, the most consistent findings have been
obtained with the measurement of CSF concentrations of
Ab peptide (Ab42), total Tau (T-Tau) and phosphorylated
Tau (P-Tau). AD patients characteristically display low
concentrations of Ab42 and high concentrations of T-Tau
and P-Tau. This pattern of CSF biomarkers is commonly
referred to as the ‘AD signature’ in the CSF. The afore-
mentioned biomarkers reflect core pathophysiological fea-
tures of the disease [46], and have been validated in post
mortem studies [47-49]. Increased concentration of T-Tau
may be a less specific marker of axonal damage, as it can
be found in vascular and other neurodegenerative demen-
tias in addition to AD (for example, prion diseases). How-
ever, it bears a positive correlation with the speed and the
magnitude of the neurodegenerative process. Decreased
Ab42 and increased P-Tau are more specific to AD. Ab42
is a byproduct of the abnormal processing of the amyloid
precursor protein (APP) leading to amyloidogenesis and
formation of neuritic plaques. In addition, decreased con-
centrations of Ab42 likely reflect its deposition in plaques,
preventing its clearance through the CSF P-Tau illustrates
the cytoskeletal changes that arise from the deregulation
of microtubule homeostasis and ultimately cause axonal
dysfunction and neuronal death. This marker is more spe-
cifically associated with AD, given the central role of Tau
hyperphosphorylation in the formation of paired helical
filaments (PHFs) and neurofibrillary tangles [50].
To date, over 100 studies have been published to sup-
port the notion that this AD-positive CSF pattern has
good diagnostic accuracy to distinguish between normal
ageing and AD (> 85%) and a positive predictive value (>
90%) to determine the dementia outcome in patients with
MCI [51]. However, in the differential diagnosis of estab-
lished dementia syndromes, the sensitivity/specificity pro-
file to differentiate AD from other dementias is
significantly lower [52]. Large-scale longitudinal studies of
MCI cohorts consistently demonstrated that the presence
of the ‘AD signature’ in the CSF has a good diagnostic
accuracy (that is, >80%) discriminating patients with MCI
who progress to AD (’MCI converters’) from those who
remain cognitively stable (’MCI-stable’ patients) and
healthy controls [51], as well as those MCI patients who
progress to non-AD dementias [53]. These sets of data
have been extensively replicated by different research
groups worldwide [54-57]. Findings are largely confirma-
tory, as reinforced by a recent meta-analysis [58]. Taken
together, these studies provide compelling evidence that
the ‘AD signature’ in the CSF is a strong predictor of
dementia outcome. MCI patients who convert to AD have
a CSF biomarker pattern indistinguishable to that found in
patients with dementia of the AD type; and MCI patients
with progressive deficits (albeit not severe enough to char-
acterize conversion) have a similar pattern to the former
patients. Conversely, MCI patients with unstable (transi-
ent) MCI and those who display non-progressive deficits
over time have a CSF biomarker pattern very similar to
that found in healthy older adults.
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However, a few methodological limitations need to be
overcome before this knowledge can be translated into
practical clinical practice. Although the determinations
of CSF concentrations of these biomarkers using
enzyme-linked immunosorbent assay (ELISA) or multi-
plex techniques (for example, xMAP; Luminex, Austin,
TX, USA) have low coefficients of intralaboratory varia-
bility (5% to 10%), the high interlaboratory variation (20%
to 30%) is a major obstacle for the comparison of data
generated in different settings. Multiple sources of bias
include preassay conditions (that is, lumbar puncture
protocol, sample handling and aliquot storing prior to
experimentation), intra-assay conditions (different meth-
ods and protocols for the determination of the concen-
trations of biomarkers), and post assay variations (for
example, definition of norms for patients and controls to
guide the interpretation of results) [59]. This situation is
a major limitation for the establishment of multicentric
cooperation. The establishment of gold-standard proto-
cols to be shared by distinct laboratories [60] and the
recent launch of a multicentric quality control program
with over 40 laboratories around the world will hopefully
overcome these limitations in the near future.
New technologies targeting Ab oligomers in the CSF
will add important insights in this field in forthcoming
years. The neuropathology of AD has been linked to the
accumulation of non-fibrillar forms of neurotoxic Ab
oligomers. There is evidence that soluble Ab oligomers,
more than amyloid fibrils per se, play a critical role trig-
gering early pathological events of the amyloid cascade.
High levels of Ab oligomers are observed in the brain
and in the CSF of patients with AD, underlining their
potential for the early diagnosis of the disease [61]. In a
recent study using a specific method for the detection of
high molecular weight (40-200 kDa) Ab species in the
CSF, Fukumoto et al. [62] showed that the measurement
of Ab oligomers might be more accurate differentiating
patients with MCI and AD from normal controls, as
compared to the usual methods based on fibrillar forms
of the peptide. Oligomerization partially explains the
lowering of Ab42 in the CSF of patients with AD, since
the presence of Ab oligomers can interfere with the ana-
lyses of the peptide by conventional methods, causing
underestimation of Ab levels due to epitope masking
[63]. Therefore, the determination of Ab oligomers in
the CSF, in addition to being useful as a diagnostic mar-
ker for AD, can be also viewed as a potential surrogate
marker for disease severity [62].
Structural and functional neuroimaging
The substantial development of neuroimaging technolo-
gies in the last decade has contributed decisively to the
search for non-invasive methods to ascertain the patho-
logical changes that evolve in the AD brain. These
advances result from new protocols for the analysis of
structural imaging (such as volumetric assessments of
regions of interest and voxel-based morphometry based
on statistical maps) [64] and functional imaging with
PET, addressing the metabolic changes that presumably
antedate structural damage. More recently, the investi-
gation of AD-specific biomarkers has been made possi-
ble with PET tracers that allow the in vivo intracerebral
imaging of amyloid and Tau.
Structural changes in the brain in AD are mostly
represented by global cerebral volumetric reduction,
increased ventricular volumes and regional atrophy in
structures of the medial temporal lobe (hippocampal
formation and enthorinal cortex) [65]. Topographic gray
matter loss correlates with Braak stages and may already
be present in patients with very mild AD; such findings
parallel the early cognitive symptoms found in the pre-
dementia phase of AD [8]. In comparison to AD,
patients with MCI show a relative preservation of cere-
bral structures; however, these patients may have mild,
but significant, volumetric changes and decreased corti-
cal thickness in specific brain regions [65-67]. Increased
grey matter loss is found in converters as compared to
stable MCI subjects; these patients display volumetric
reductions in hippocampal and parahippocampal struc-
tures and, to a lesser extent, in the posterior cingulate
cortex, middle and inferior temporal gyri, fusiform
gyrus, posterior cingulate gyrus, precuneus, temporopar-
ietal junction, and frontal cortex [68-73]. A recent meta-
analysis study indicated smaller left hippocampal
volumes in converter versus stable MCI patients [74].
With respect to functional neuroimaging, the main
metabolic changes observed in AD are global reductions
in cerebral metabolism and perfusion as shown by FDG-
PET and SPECT scans. These changes are observed in
the temporoparietal junction, temporal, parietal and fron-
tal lobes, hippocampal formation and posterior cingulate
cortex [75,76]. As is the case for most methods of struc-
tural neuroimaging, patients with MCI show a pattern of
changes that is intermediate between healthy older peo-
ple and patients with AD [77,78]. Likewise, in prospective
studies, MCI converters show a pattern of cerebral hypo-
metabolism that is largely similar to that found in
patients with mild AD, in particular in the posterior cin-
gulate cortex and the hippocampal regions [79-83].
The development of new technologies to visualize and
quantitate Ab and Tau deposits in vivo within the brain
is undoubtedly a major achievement in the field AD bio-
marker research. The first compound to be developed for
human experimentation was the ‘Pittsburgh Compound
B’ (PiB) [84], which is an 11C-labelled compound that
binds intracerebral Ab in mature amyloid plaques [85].
Other compounds are the amyloid-affinity compound
18F-BAY94-9172 [86], and the dual amyloid and Tau-
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binding compound 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)
amino]-2-naphthyl}ethylidene)malononitrile (FDDNP),
which has the additional property of mapping neurofi-
brillary tangles in addition amyloid plaques [87].
In AD, there is an increased global cortical and regional
retention of PiB and other compounds, particularly in the
cingulate, temporal, parietal and frontal cortices [88]. Stu-
dies with amyloid imaging in mild AD have a very high
sensitivity (over 90%), but the specificity is age dependent,
due to the increasing deposition of Ab over time in
healthy older people. Important studies have shown nega-
tive correlations between intracerebral amyloid content (as
shown by PiB scans) and CSF concentrations of Ab42 in
patients with mild AD as compared to controls [89,90].
As observed in other neuroimaging modalities, the PiB
retention rates are also increased in patients with amnestic
MCI, albeit less than in AD patients. Positive PiB scans
predict conversion, and PiB retention (global and regional)
correlates with cognitive performance [91,92]. In a pro-
spective study, PiB-positive MCI patients had a higher
conversion rate than PiB-negative patients; in addition, the
amyloid load was negatively associated with time to con-
version [93]. PiB retention was also observed in older sub-
jects without cognitive complaints or dementia; it is
noteworthy that a higher retention at baseline was asso-
ciated with a worse cognitive performance and predicted a
faster decline [94-97]. These findings are largely compati-
ble with the CSF biomarkers as predictors of cognitive
deterioration in non-demented older adults [98]. Finally,
the combination of functional and structural imaging data
reinforces the notion that the accumulation of Ab in the
AD brain precedes the onset of functional and structural
changes (that is, high PiB retention correlates with the AD
signature in the CSF and may be detected in the absence
of significant brain atrophy [99-104]).
Summary and future directions
A well defined pattern of CSF and imaging biomarkers
can be characterized in AD. These biomarkers reflect
core pathological changes that evolve in the prodromal
phase of AD, including the predementia, and presum-
ably the presymptomatic, stages of the disease.
AD-related biomarkers identify with good accuracy non-
demented patients with mild cognitive dysfunction who
will ultimately progress to dementia, differentiating con-
verters from healthy individuals and subjects with stable,
non-progressive cognitive deficits. In addition, AD bio-
markers may help to discriminate, although with lower
accuracy, slow from rapid converting cases of MCI. The
main biomarkers under investigation and their relation-
ship with the pathological process in AD can be grossly
subdivided into two main categories: (i) those reflecting
core neuropathological changes of AD at the molecular
level (for example, CSF biomarkers and amyloid imaging
with PET), and (ii) downstream biomarkers reflecting
secondary changes to brain structure and function,
namely volumetric and metabolic changes to temporo-
medial structures (Table 1).
Table 1 Biomarkers under investigation for Alzheimer’s disease
Correlates: Method/source: Alzheimer’s disease-related biomarkers:
Molecularcore neuropathology Cerebrospinal fluid - Concentrations of amyloid-b42;
- Total Tau and phosphorylated Tau;
In vivo molecular imaging - Intracerebral beta-amyloid load (e.g., PiB-PET, 18F-BAY94-9172);
- Intracerebral aggregates of amyloid and tangle Tau(e.g., 18F-FDDNP);
Downstreamsecondary changes Structural neuroimaging(MRI) - Regional (medial temporal) atrophy (MRI)
- Volumetry of hippocampus/entorhinal cortex (MRI)
- Rate of brain/regional atrophy (MRI)
- Voxel-based morphometry (VBM)a
- Diffusion tensor imaging (DTI)a
Functional neuroimaging(PET, SPECT, fMRI) - Metabolic changes (FDG-PET)
- Regional perfusion (SPECT)
- Functional MRIa and MRI perfusion-Functional connectivitya
Neurochemistry - Proton spectroscopy (+H-MRS)a
Associatedhomeostatic changes Peripheral fluids(serum, plasma, platelets) - Inflammatory markers (interleukins, cytokines)a
- Oxidative stress (isoprostanes)a
- Ab40/Ab42 ratio*;
APP ratioa
- Glycogen synthase kinase-3b activitya
- Other markers of synaptic damage/neurodegenerationa
a Less validated biomarkers; Ab, amyloid-beta peptide; APP, amyloid precursor protein; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy;
PET, positron emission tomography; SPECT, single-photon emission tomography; FDG, fluoro-deoxyglucose; PiB, Pittsburgh Compound B; FDDNP, 2-(1-{6-[(2-[18F]
Fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile.
Forlenza et al. BMC Medicine 2010, 8:89
http://www.biomedcentral.com/1741-7015/8/89
Page 9 of 14
In addition to providing biological support to the clin-
ical diagnosis of AD, the establishment of biomarker
technology has also favored the development of other
important areas of research. First, the use of biomarker
information can add important benefits to intervention
trials, particularly with pharmaceutical compounds with
disease-modifying properties. AD-positive biomarkers
can be regarded as stringent inclusion criteria, defining
more homogeneous samples of patients and therefore
increasing the probability of success of randomized clin-
ical trials; furthermore, the longitudinal reassessment of
biomarkers can be viewed as a way to monitor specific
biological outcomes of interventions with antidementia
drugs, or to define proof-of-concept mechanisms of
action of candidate drugs.
Secondly, given the long preclinical phase of AD, another
potential use of biomarkers is the characterization of early
signs of the disease in presymptomatic stages of the pro-
cess. Evidence from epidemiological and autopsy studies
support the hypothesis that there is a temporal lag of
approximately a decade between significant accumulation
of amyloid in the brain and the clinical onset of dementia.
The percentage of amyloid-positive normal individuals
detected at one given age closely parallels the percentage of
individuals diagnosed with AD dementia a decade later
[13]. In a longitudinal study with healthy older adults,
changes in CSF biomarker levels associated with AD corre-
lated with decline in cognitive functions, suggesting that
these biomarkers may help identify early neurodegenerative
processes of AD [105,106]. These notions have oriented
recent task forces to develop diagnostic criteria for preclini-
cal AD [107].
Finally, the actual prevention of dementia will be a
tangible goal when the aforementioned challenges have
been accomplished. In other words, the identification of
individuals at high risk for developing dementia (includ-
ing cognitively normal individuals at the presympto-
matic stage of AD) and the effective treatment with
pharmaceutical compounds with disease modifying
properties will ultimately preclude (or at least attenuate)
the subsequent neurodegeneration and eventual cogni-
tive decline (Table 2).
Table 2 Putative clinical and biological markers of the distinct stages in the AD continuum (from normal cognition to
dementia), and respective therapeutic interventions (clinically supported therapies and potential interventions with
candidate drugs/strategies that still require experimental validation)
Clinical stage Underlying pathological
mechanisms
Putative clinical and biological
markers
Potential therapeutic interventions
Asymptomatic
(pre-clinical AD)
Intracerebral accumulation
of amyloid-b
- CSF concentrations of Ab42 - Cognitive reserve (education and level of intellectual
functioning)
- Molecular imaging (PiB-PET) - Lifestyle changes (nutrition, physical fitness, reduction of
stress)
- Autossomal dominant mutation
(APP, PS1, PS2 genes)
- Management of underlying factors (cardiovascular risk
factors, toxic and comorbid conditions)
Prodromal (pre-
dementia AD)
Ab-related pathology
(amyloid cascade)
- Episodic memory impairment
(amnestic MCI)
- Anti-amyloid therapy:
* immunotherapy anti-Ab
* modulation of b- and g-secretase
* anti-fibrillization agents and chelators
- CSF concentrations of Ab42
- Molecular imaging (PiB-PET)
- Autossomal dominant mutation
(APP, PS1, PS2 genes)
Tau-related pathology
(neurodegeneration)
- Multiple-domain amnestic MCI - All above
- CSF concentrations of Tau(total
and phosphorylated Tau)
- Neuroprotective approaches(antioxidants, anti-
inflammatory drugs)
- Brain metabolism (FDG-PET) - Tau-related therapies(GSK inhibitors, lithium)
- Medial temporal lobe atrophy
(volumetric MRI, VBM)
- Neurorestorative approaches(NGF, BDNF, stem cells)
Clinical dementia Neuritic
plaquesNeurofibrillary
tangles
- Neuropsychological tests - Antidementia drugs (cholinesterase inhibitors, memantine)
- Functional assessment - Cognitive training
- Structural imaging (CT/MRI) - Functional rehabilitation (ADLs)
- Neuropathology - Psychoeducation (caregivers)
AD, Alzheimer’s disease; MCI, mild cognitive impairment; Ab, amyloid-beta peptide; CSF, cerebrospinal fluid; APP, amyloid precursor protein; PS, pre-senilins 1 and
2; PET, positron emission tomography; PiB, Pittsburgh compound B; FDG, fluorodeoxyglucose; CT, computerized tomography scan; MRI, magnetic resonance
imaging; VBM, voxel-based morphometry.
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Conclusions
Individuals with mild cognitive deficits do display signs
of AD pathology, since approximately 50% are already
in Braak neurofibrillary stage III or higher, and 20% are
likely to be in more advanced stages of neuropathology
[108]. It is likely that those with considerable brain or
cognitive reserve will be able to compensate cognitive
deficits until very close to the onset of the dementia,
rendering the diagnostic investigation of predementia
AD based solely on cognitive measures insensitive.
Therefore, the development of biomarkers for AD is
needed to target the severity of underlying brain pathol-
ogy independently of brain reserve.
The measurement of AD-related biomarkers in the CSF
or by neuroimaging methods improves diagnostic accu-
racy and predictive value of the clinical classification of
patients according to the definition of MCI. The charac-
terization of early clinical signs of AD (compatible with
episodic memory impairment) with the support of one or
more well established biomarkers has been recently pro-
posed as the core feature required for the diagnosis of
AD in the predementia stages [109]. This supports the
clinical use of definition of MCI in the search for cases of
prodromal AD [110]. The accurate identification of sub-
jects with underlying AD pathology is an acute require-
ment for future trials with disease-modifying drugs
[111,112]. However, as outlined in this review, there are
critical methodological problems that still need to be
overcome in order to enable the translation of this robust
experimental knowledge into clinical practice.
In spite of the relevant contribution of clinical and
biomarker research in the early diagnosis of AD, or even
the characterization of the disease in asymptomatic or
minimally symptomatic individuals, the use of these
technologies raises the possibility of misidentification of
cases. The incorrect classification of individuals as being
at high risk for AD may lead to undue alarm and con-
cern, in addition to unnecessary interventions. There-
fore, before biomarker profiles are used in the general
population, high specificity should be demonstrated in
multiple populations. For the time being, the careful and
comprehensive clinical judgment is mandatory to guide
therapeutic decisions, even though the diagnostic
hypothesis may be strongly reinforced by a positive bio-
marker. In the prospect that safe and effective, experi-
mentally validated disease-modifying therapies become
available in the near future, the reliable early detection
of AD in the general population will become an essen-
tial tool in the prevention of this illness [113,114].
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